The value of C-reactive protein in screening for future coronary heart disease events

Journal of Medical Screening

Volumn 16, Issue 4, 2009, Pages 212-214

  Wald, David S ^a   Kasturiratne, Anuradhani ^a   Bestwick, Jonathan P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CORONARY ARTERY DISEASE; HUMAN; METABOLISM;

C-REACTIVE PROTEIN; CORONARY DISEASE; HUMANS;

EID: 75149184099     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2009.009087     Document Type: Article

References (28)

1. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38:217-231
2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363
3. Kones R. The Jupiter study, CRP screening, and aggressive statin therapy - implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis 2009;3:309-315
4. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-1565
5. Gram J, Bladberg EM, Moller L, Sjol A, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Int Med 2000;247:205-212
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN for the MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-547
7. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, et al. Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108:2453-2459 (Pubitemid 37444405)
8. Pischon T, Mohlig M, Hoffmann K, et al. Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels. Eur J Epidemiol 2007;22:429-438
9. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387
10. Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-Reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006;26:2745-2751
11. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002;55:445-451
12. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Eng J Med 2000;343:1148-1155
13. Folsom AR, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002;144:233-238 (Pubitemid 34879645)
14. Lowe GDO, Sweetnam PM, Yarnell YWG, et al. C-reactive protein, Fibrin D-Dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterior Thromb Vasc Biol 2004;24:1957-1962
15. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;338:973-979
16. St-Pierre AC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men: a 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 2005;182:315-321
17. Lowe GDO, Yarnell JWG, Rumley A, et al. C-reactive protein, Fibrin D-Dimer, and incident ischemic heart disease in the Speedwell Study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21:603-610
18. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 2000;342:836-843
19. Arima H, Kubo M, Yonemoto K, et al. High-sensitivity, C-reactive protein and coronary heart disease in a general population of Japanese: The Hisayama Study. Arterioscler Thromb Vasc Biol 2008;28:1385-1391
20. Woodward M, Rumley A, Welsh P, et al. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haem 2007;5:1795-1800
21. Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. PLoS ONE 2008;3:e1395
22. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-422
23. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from theWomen's Health Initiative Observation Study. JAMA 2002;288:980-987
24. van der Meer IM, de Maat MPM, Kiliaan AJ, et al. The value of C-reactive protein in cardiovascular risk prediction (The Rotterdam Study). Arch Int Med 2003;163:1323-1328
25. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Atheroscler Thromb Vasc Biol 1997;17:1121-1127
26. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The Cardiovascular Health Study. Circulation 2005;112:25-31
27. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003;107:499-511
28. Ridker PM, Danielson E, Fonesca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207